Physician profile
James T Mclaughlin
NPI 1568453124
$2,587.74
in general payments reported to CMS, 2019-2025
36 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $89.99 · 2021: $138 · 2022: $383 · 2023: $528 · 2024: $460 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $417.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $289.13 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $148.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.64 | 2020-2025 | Ofev, Cyltezo, Jardiance |
| Lilly USA, LLC | $134.00 | 2022-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $74.02 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $72.11 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.08 | 2021-2024 | Xifaxan |
| Mannkind Corporation | $59.40 | 2022 | |
| Neurocrine Biosciences, INC. | $53.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.77 | 2023 | |
| Beckman Coulter, INC. | $49.97 | 2024 | Access 2 |
| Phathom Pharmaceuticals, INC. | $49.91 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $46.92 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44.30 | 2023-2024 | |
| Dexcom, INC. | $31.98 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $31.89 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $29.91 | 2019-2020 | |
| Axsome Therapeutics, INC. | $25.92 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $23.96 | 2023 | Trintellix |
| Radius Health, INC. | $22.70 | 2025 | Tymlos |
| Amarin Pharma, INC. | $21.54 | 2019 | |
| Ibsa Pharma INC. | $20.89 | 2024 | Licart, Tirosint |
| Astellas Pharma US INC | $20.03 | 2023 | Veozah |
| Agios Pharmaceuticals, INC. | $19.39 | 2025 | Pyrukynd |
| Corcept Therapeutics | $18.74 | 2025 | Korlym |
| Exelixis INC. | $18.05 | 2025 | Cabometyx |
| Mylan Specialty L.P. | $17.74 | 2022 | |
| Horizon Therapeutics Plc | $15.91 | 2023 | Krystexxa |
| Braemar Manufacturing, LLC | $14.49 | 2019 | |
| Esperion Therapeutics, INC. | $14.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.28 | 2022 | |
| Sumitomo Pharma America, INC. | $12.84 | 2023 | Gemtesa |
| Eisai INC. | $12.36 | 2022 | |
| Merck Sharp & Dohme LLC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.